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Abstract: To illustrate the process of addressing adverse preclinical findings (APFs) as outlined in the first part of this
review, a number of cases with unexpected APF in toxicity studies with drug candidates is discussed in this second part.
The emphasis is on risk characterization, especially regarding the mode of action (MoA), and risk evaluation regarding
relevance for man.  While severe APFs such as retinal toxicity may turn out to be of little human relevance, minor
findings particularly in early toxicity studies, such as vasculitis, may later pose a real problem.  Rodents are imperfect
models for endocrine APFs, non-rodents for human cardiac effects.  Liver and kidney toxicities are frequent, but they
can often be monitored in man and do not necessarily result in early termination of drug candidates.  Novel findings
such as the unusual lesions in the gastrointestinal tract and the bones presented in this review can be difficult to explain.
It will be shown that well known issues such as phospholipidosis and carcinogenicity by agonists of peroxisome
proliferator-activated receptors (PPAR) need to be evaluated on a case-by-case basis.  The latter is of particular interest
because the new PPAR α and dual α/γ agonists resulted in a change of the safety paradigm established with the older
PPAR α agonists.  General toxicologists and pathologists need some understanding of the principles of genotoxicity and
reproductive toxicity testing.  Both types of preclinical toxicities are major APF and clinical monitoring is difficult,
generally leading to permanent use restrictions.    (J Toxicol Pathol 2010; 23: 213–234)
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Introduction
In the first part of this review processes for dealing with
unexpected adverse preclinical findings (APFs) were dis-
cussed and an overview over APFs associated with drug
classes and safety issues often encountered in preclinical
studies was given.  The various steps in dealing with APFs
involve: 
• Hazard recognition, which also includes the need to
verify if the observed effect is indeed a biologically sig-
nificant APF
• Hazard characterization, which serves to better under-
stand the APF including aspects such as quantitative
dose-response, severity, reversibility, and most impor-
tant, if possible, potential pathogenic pathways and
underlying mode of action (MoA) of the drug candidate
leading to the APF in question
• Risk evaluation, essentially an intellectual process,
including 
° MoA aspects, as far as established 
° the relevance of the APF for man
° and—particularly if relevance for man can not be
excluded with certainty—calculation of safety
ratiosa between exposure at the no observed
adverse effect level (NOAEL)1 in the most sensi-
tive and for man relevant animal species and expo-
sure at the maximal (anticipated) human dose 2. 
To arrive at a full weight of evidence (WoE) evalu-
ation other factors such as therapeutic indication,
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aThe safety ratio is also often called “safety factor” and in some regions
“safety margin”.  As especially the latter term is partly used in a differ-
ent way (see first part of the review), it is important to define the exact
meaning of such terms.214 Adverse Preclinical Findings—2
medical need, and alternative drugs already on the
market must also be taken into account
• Risk management to minimize the risk of humans par-
ticularly in early clinical trials
Toxicologic pathologists together with toxicologists
play an important role for recognizing potential APFs: They
contribute to resolve issues related to such findings and to
support the risk management process.  They must feel
accountable for the health of humans to be exposed to the
drug candidate, but must also avoid being overcautious, thus
preventing potentially useful drugs to reach the market.
This second part of the review concentrates on a more
detailed discussion of selected APFs of drugs as far as possi-
ble with reference to their MoA and regarding their rele-
vance for man.  Examples will cover morphologic toxicity
and tumorigenicity as well as some additional aspects of
functional toxicity.  Experience regarding APFs in reproduc-
tive and genotoxicity studies will be included as far as rele-
vant to the general toxicologist and toxicologic pathologist.
Unsuccessful attempts to resolve preclinical toxicity
issues may not be published.  However, if an APF did not
stop drug development, findings are often mentioned in the
package insert.  It may be somewhat comforting that most
package inserts actually show that APFs were detected dur-
ing the development of the drug.  Successful “troubleshoot-
ing” results are sometimes published, as acceptance for
publication in a recognized peer-reviewed scientific journal
may support registration.  Last but not least, personal experi-
ence of the authors has played an important role in writing
this review. 
Examples of Addressing APFs
General Toxicity
Neural toxicity
Nerve cells are special, as after birth they can not mul-
tiply and therefore do not regenerate with partial exception
of severed nerve processes.  CNS toxicity in preclinical
safety studies is a severe APF and relatively rare with drug
candidates, but a number of industrial chemicals are known
to be neurotoxic3–5.  The developing brain appears to be par-
ticularly vulnerable4.  CNS toxicity may also be secondary
e.g. to seizures6, disturbance of circulation or exhaustion of
nerve cells by excitatory amino acids7–9.  For functional CNS
toxicity see first part of this review.
Peripheral neuropathy, also not frequently seen with
drug candidates, may occur e.g. because of prolonged
hypoglycemia with antidiabetic drugs at high doses10, 11.
Retinal toxicity is a special type of neural toxicity and needs
to be distinguished in particular from light-induced retinopa-
thy of albino rodents12.  Some drugs which induce retinotox-
icity in laboratory animals are discussed in the following
paragraph.
Retinal toxicity: The eye is one of those organs where
toxicity is not acceptable, particularly if potentially leading
to permanent visual impairment.  Early retinal toxicity can
manifest itself already in a two week study, initially by a
subtle decrease in the number of nuclei e.g. of the outer
nuclear photoreceptor layer and retinal thinning.  With
longer treatment, nuclear layers may disappear, and the pig-
ment epithelial layer may become disrupted.
Do such findings mean that development of the drug
candidate needs to be abandoned? Not necessarily, as illus-
trated by a number of drugs on the market, which produce
toxicity in laboratory animal eyes—though often only in one
animal species or strain, mainly in albino rats— but are
deemed safe for humans13.  The retina of rats and mice is
damaged e.g. by ribavarin used in case of hepatitis C and by
various lipid lowering drugs.  A number of animal species is
adversely affect by nalidixic acid14, a drug against urinary
tract infection, and tranexamic acid15 against angioneurotic
edema.  However, some drugs such as hydroxychloroquine,
are toxic also for the human eye and may lead to irreversible
retinopathy16, 17.
Besides being hepatotoxic, adversely affecting the
endocrine and cardiovascular system, and inducing phos-
pholipidosis, some CNS drugs are also known to be retino-
toxic in animals, partly at relatively low doses.  Such animal
retinotoxicity was seen e.g. with pregabalin (neuropathic
pain) in albino rats; pramipexole (Parkinson’s disease) in
albino rats, but not in pigmented rats, albino mice, monkeys,
and minipigs; aripiprazole (psychosis) in albino rats, but not
in albino mice and monkeys; and with citalopram in albino
rats18.  However, no retinal changes were detected in humans
treated with these drugs by careful eye monitoring.
If retinal toxicity is observed, it is not sufficient to refer
to literature or other sources of information related to the
APF.  It is necessary to characterize the hazard, that is to
• Show that e.g. only one species or strain is affected, or
—if two rodent species (rats and mice) are affected—
non-rodents (e.g. dog and monkey) are without eye
lesions
• Define when the lesion starts to appear 
• Determine the exact NOAEL, e.g. by using more sensi-
tive investigations such as morphometry or, if deemed
necessary, electron microscopy (EM).
In addition to ophthalmoscopy, electroretinogram
(ERG) investigations in animals may have to be considered.
However, recording and interpreting ERGs is a demanding
expert task.  Species-related differences regarding the func-
tion of the retina limit the predictive value of these tools19, 20.
At least initially it is important to monitor humans by oph-
thalmoscopy, vision tests, ERG, etc. in clinical studies with
drugs which, based on preclinical findings, may be oculo-
toxic.  Binding of drugs to eye melanin of laboratory animals
is not predictive of ocular toxicity21.
Endocrine system including effector organs
Increased incidences of endocrine tumors are seen with
many drug candidates in chronic toxicity and lifetime bioas-
say studies.  These tumors generally result from disturbance
of the hormonal balance.  They are often due to the specific
endocrine physiology of rodents (for more details see the
first part of this review) and therefore without relevance toEttlin, Kuroda, Plassmann et al. 215
man 22.  A few examples are discussed below.
Uterine tumors: Dopaminergic drugs have endocrino-
logical and neurological clinical indications.  Among them
are ergot alkaloids which, based on their structure-activity
relationship, can be divided into three classes: Lysergic acid
amines (e.g. bromocriptine), clavines (e.g. pergolide), and 8-
α-aminoergolines (e.g. lisuride and mesulergine).  Dopamin-
ergic ergot alkaloids have significant endocrine effects in
rodents, particularly in rats, through their inhibitory effect on
the secretion of prolactin (PRL) from the anterior pituitary23.
The elucidation of the MoA of dopaminergic drug candi-
dates in laboratory animals also illustrates the importance of
carefully planning additional experiments, as an explanation
for the uterine findings is only possible taking into account
the age-specific sex hormone climate in aging rats. 
Bromocriptine was found to induce squamous cell
metaplasia of the uterine endometrium in a chronic (53
week) rat study at the high dose of 82 mg/kg bw/day in feed
admixture.  The typical appearance with squamous cell
metaplasia, polypoid structures, and some stromal inflam-
mation is shown in Fig. 1.
In the lifetime bioassay with lower doses (1.8, 9.9, and
44.5 mg/kg bw/day in feed) these lesions had progressed in
the mid and high dose to uterine adenocarcinomas as shown
in Fig. 2 with mostly tubular structures of various sizes,
which are partly multilayered and show cellular and nuclear
polymorphism, as well as diffuse infiltration into the myo-
metrium.
The MoA of bromocriptine leading to these uterine
changes is summarized in Table 1.
Because of high PRL and low luteinizing hormone
(LH), untreated older rats stop cycling and remain in diestrus
(pseudopregnancy) with relatively high progesterone pro-
duction.  By lowering PRL bromocriptine treatment initiates
regular cyclical activity, but this is short-lived, as the insuf-
ficient preovulatory LH surge can not trigger ovulation thus
leading to cystic follicles.  As a consequence of the lack of
estrous cycles, also corpora lutea tend to persist.  However,
because of the low PRL levels these corpora lutea do not pro-
duce significant amounts of progesterone.  Therefore, the
estrogen/progesterone ratio is higher in bromocriptine-
treated rats, which leads to squamous endometrial metapla-
sia.  This physiological reaction facilitates endometritis and
pyometra, which through irritation results in increased cell
proliferation and, if sustained, may give rise to neoplasia. 
No comparable uterine findings were detected in a 52
week dog study or in a carcinogenicity study in mice.  Also,
in clinical studies bromocriptine did not influence follicle
stimulating hormone (FSH), LH, estradiol or progesterone
levels in female patients.  Endometrial biopsies of chroni-
cally treated patients did not show any drug-related
changes24.  The uterine APF in rats is without relevance for
women and considered to be an exaggerated pharmacody-
namic effect of bromocriptine specific for aging female
rats23, 24.
Leydig cell tumors: Mesulergine is an 8 α-aminoer-
goline with antagonistic and agonistic activity on the D-2
dopamine receptor.  It was developed for the treatment of
hyperprolactinemia and of Parkinson’s disease.  For reasons
not related to the APF discussed here, it did not reach the
market, but a successor drug with similar properties has been
registered as drug. 
In the carcinogenicity study of 129 weeks with
mesulergine at doses of 0.11, 0.42, and 1.7 mg/kg bw/day in
feed admixture, male Wistar rats developed at all doses an
excess of Leydig cell (LC) tumors morphologically not dis-
tinguishable from spontaneous tumors commonly seen in old
male Wistar rats.  The typical appearance of this tumor and
the precursor lesion, namely focal and diffuse LC hyperpla-
sia, is shown in Fig. 3.  The seminiferous tubules are partly
Fig. 1. Squamous cell metaplasia of the endometrium of a female
OFA rat treated in feed for 53 weeks with 82 mg/kg bw/day of
bromocriptine. H&E, lens 10×.
Fig. 2.  Uterine adenocarcinomas of an OFA rat treated in feed for
100 weeks with 44.5 mg/kg bw/day of bromocriptine. H&E,
lens 10×.216 Adverse Preclinical Findings—2
atrophic, which may be due both to pressure produced by the
large LC tumors and the disturbed endocrine regulation. 
Other dopaminergic compounds induced also variants
of LC tumors characterized by glandular and/or tubular
structures (single columnar layer of cells, occasionally with
papillary projections), including some with malignant fea-
tures, such as cellular atypia and invasion of the capsule and/
or blood vessels25.  The glandular/tubular structures stained
immunohistochemically as LC, thus confirming that this
variant is a form of LC metaplasia. 
The proposed MoA26, 27 is shown in Table 2 and is
related to the PRL lowering effect of mesulergine and the
resulting reduced sensitivity of LC to LH because of fewer
LH receptors in LC.  Rat LC also possess LH releasing hor-
mone (LHRH) receptors28.  Therefore, in addition to
increased LH levels, increased levels of LHRH contributed
to the hyperplastic and neoplastic response of the LC. 
The occurrence of variants of LC tumors did not change
the final assessment that the syndrome appears to be rat-spe-
cific, which was confirmed by members of a workshop on
rodent LC adenomas and human relevance29.  Similar
changes are not found in other laboratory animal species or
man.  Increased LH levels in men are seen e.g. in the
Klinefelter Syndrome, a numerical chromosome aberration
during gametogenesis with one (occasionally several) addi-
tional X chromosome(s) (XXY or XXXY genotype), and do
not result in LC tumors. 
Other drugs—such as busereline, carbamazepine, cime-
tidine, finasteride, flutamide, gemfibrozil, histrelin, hydrala-
zine, indomethacin, isradipine, lactitol, leuprolide,
metronidazole, mesulergine, nafarelin, norprolac, and
vidarabine—may also disturb the closed-loop feedback
mechanism of the hypothalamo-hypophyseal-gonadal axis28.
Although the precise cause of the perturbation may vary
depending on the drug type, the end result appears to be
similar26, 28.  However for new drug candidates the hypothe-
sis of a hormonal disturbance in laboratory animals needs to
be proven on a case-by-case basis29.
Pituitary tumors:  Tumors of the pituitary are frequent
in rodent bioassays, sometimes in a dose-dependent manner,
suggesting a causal relationship with treatment.  The follow-
ing case triggered a number of additional investigations, but
could not be completely resolved regarding the MoA.  How-
ever, biomarkers identified during the various steps of
addressing the APF allowed monitoring of man for the cor-
responding disturbance and allaying concern.  In addition,
clinical data—the drug was on the market for many years
prior to the tumor finding—did not reveal any evidence that
these rat pituitary tumors were relevant to man.
Salmon and porcine calcitonin are calcium-lowering
hormones used e.g. for the treatment of hypercalcemia asso-
ciated with bone metastases and postmenopausal osteoporo-
sis.  The drugs are also used for many other indications, often
off-label, and therefore an increased incidence of tumors in
the pars distalis of the pituitary in rats treated for 52 weeks
Table 1.  Endocrine Reproductive Climate in Aging Female Rats and Mode of Action of Bromocriptine Leading to Uterine
Tumors (modified after23)
Endocrine axis Effects seen in
Control aging rat Bromocriptine treated aging rats
Pituitary Low LH  Low LH
High prolactin Bromocriptine treatment-related decrease of prolactin
Ovary → Persisting corpora lutea → Often cystic follicles with persisting corpora lutea
→ High progesterone → Low progesterone
Estrogen normal Both effects mainly because of low LH
Estrogen normal
Uterus Progesterone dominance Estrogen dominance (ratio progestone/estrogen decreased) 
→ Pseudopregnancy → Squamous metaplasia,  
     with prolonged diestrus      endometritis, pyometra, neoplasia
Fig. 3. Leydig cell hyperplasia (one focus in the center of the figure)
and adenomas (one seen on the right side of the figure) of the
testis of a Kfm:WIST rat treated in feed for 129 weeks with
1.7 mg/kg bw/day of mesulergine. H&E, lens 10×. Ettlin, Kuroda, Plassmann et al. 217
with subcutaneous doses of 1.25, 5.0, or 80.0 IU/kg bw/day
of salmon calcitonin was of concern: Pituitary tumors were
seen in male rats at all doses and pituitary hyperplasic foci in
female rats at the high dose30.  In a follow-up study these
tumors were found to be non-functioning, that is the serum
levels of traditional pituitary hormones were not signifi-
cantly altered with exception of a two-fold increase of TSH.
However, immunohistochemical and in situ hybridization
characterization of the tumors showed that these tumors pro-
duced significant amounts of the α-subunit of the pituitary
glycoprotein hormones LH, FSH, and TSH31, 32.  This α-sub-
unit is rarely found in control and spontaneously occurring
hyperplastic or neoplastic lesions.  A time course study
revealed an increase of the serum α-subunit already after 24
weeks of treatment and was in parallel to the appearance of
histopathological lesions.  In treated human beings the gly-
coprotein α-subunit was always normal.  After many years
of repeated investigations it can be concluded that the drugs
are safe. 
Cardiovascular toxicity 
It is important to carefully examine the early short-term
studies for heart lesions33, though this does not replace func-
tional testing, mostly measurement of the QT time (see first
part of this review).  Drug candidates can exert their toxicity
via a direct action on myocytes, e.g. through cytotoxicity,
which is the case e.g. for tyrosine kinase inhibitors34, or in
connection with drug-induced metabolic disorders, e.g. dia-
betes mellitus, hyperthyroidism or phospholipidosis.
Depending on the species, cardiotoxicity can manifest itself
in different parts of the heart.  E.g. minoxidil induces arterio-
pathic changes mainly in the right atrium in dogs, but in the
left atrium in minipigs.  This can possibly be explained by
differences of the atrial vascularization: Minipigs are right
coronary artery predominant, while the left coronary artery
is dominant in most other species.  As heart and skeletal
muscles are partly significantly different35, skeletal statin
myopathies are generally not associated with significant car-
diac toxicity36–38.  However, there is evidence that besides
having a cardioprotective effect, statins may also be
cardiotoxic39–41.  In addition, it is suspected that agonists of
peroxisome proliferator activated receptors (PPAR) may not
only cause rhabdomyolysis, but also adversely affect the
heart (see section on PPAR agonists below).
Direct cardiotoxicity observed in laboratory animals is
often predictive for cardiac side-effects in man.  However,
commonly used laboratory animal species are in part quite
prone to develop cardiovascular changes.  Dogs are fre-
quently affected by spontaneously occurring vasculitis,
depending on the dog-colony.  Such lesions may be difficult
to distinguish from induced lesions42, 43. 
Hemodynamic effects of drug candidates associated
with morphological cardiotoxicity are often due to exagger-
ated pharmacological effects on myocytes, including inotro-
pic (force), chronotropic (rate), lusiotropic (relaxation), and
dromotropic (conduction) effects.   Inotropic and chronotro-
pic effects lead to a work overload with underperfusion of
areas supplied by end arteries and shortening of the diastolic
period when blood perfusion takes place.  Inotropic and
chronotropic effects are seen e.g. with isoprenalin or drugs
leading to hyperthyroidism.  Dogs are highly sensitive to car-
dioactive and vasodilating drugs, particularly to drugs lead-
ing to tachycardia44, 45.  Lesions in dog hearts associated with
tachycardia are without relevance to man.  However, if sim-
ilar findings also occur in monkeys, the issue becomes more
serious and a sufficient safety ratio is necessary.  Dromotro-
pic effects of drug candidates on the conduction system of
the heart, often the hERG channels, may lead to ventricular
blocks and arrhythmias.  QT measurements and hERG test-
ing is mainly used for screening of such effects, but positive
tests only mean that careful investigations in man are needed
to check for human relevance46, 47. 
Hemodynamic effects also include effects on blood vol-
ume e.g. by PPAR agonists48.  Vasoconstriction with
increased blood pressure and decreased end artery perfusion
can occur e.g. with noradrenalin or vasopressin.  Vasodila-
tion with decreased blood pressure, vascular wall distention,
and potentially vascular wall necrosis occurs e.g. with phos-
Table 2. Mesulergine Effect on Rat Leydig Cells (Modified after23)
Target organ axis Mesulergine treatment—Sequence of events
Hypothalamus
Reduced testosterone feedback 
→ 
Increased production of LHRH in Sertoli cells
Pituitary
Prolactin secretion decreased →
LH increase
Testis →
Leydig cells LC a) Number of LH receptors in LC decreased  LH and LHRH increase have
b) Testosterone production decreased trophic (proliferative) effect on LC
→
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phodiesterase (PDE) inhibitors and potassium channel open-
ers.  Most hemodynamic side-effects are not relevant to
man45, but this needs to be demonstrated case-by-case by
elucidating the MoA leading to the observed effect and dem-
onstration of the absence of this effect in man.  Over all,
hemodynamic effects are more difficult to elicit in rodents,
but age-related spontaneous cardiovascular diseases are fre-
quent in these species.  Also monkeys and minipigs are less
sensitive than dogs to drug-induced hemodynamic-related
cardiovascular toxicity. 
The most frequent vascular toxicity is vasculitis, which
is induced by a number of drugs such as potassium channel
opener49, 50, adenosine agonists51, endothelin receptor
antagonists52, 53, dopaminergic agonists54, and quite often by
PDE inhibitors55–60.  An example of a subacute arteritis/peri-
arteritis in the kidney of a rat treated with an undisclosed
drug is shown in Fig. 4. 
Vascular toxicity is difficult to detect during the in-life
phase of safety studies and in clinical trials, because the
available biomarkers (see below) are not that powerful and
because the MoA is generally not well understood 61.  Vascu-
lar toxicity is often seen in mesenteric vessels of rats, which
are also the site for spontaneous polyarteritis nodosa 62, pos-
sibly because the surrounding adipose tissue may not suffi-
ciently support dilated arteries and/or because these vessels
have a higher number of vasoactive receptors.  Also,
increased shear stress on the arterial wall appears to play a
role.  If exaggerated vasodilation is suspected as MoA for
vasculitis in a subacute study, it can be worthwhile to try
blocking vasodilation e.g. with vasopressin. 
Potentially useful biomarkers of cardiovascular injury
in early and later clinical trials for hazard identification,
characterization, and management in man are 
• Traditional physiological biomarkers such as arterial
pressure and heart rate 
• Cardiac troponin I and T concentrations in serum to rec-
ognize myocardial membrane disruption and myocar-
dial necrosis early
• Von Willebrand factor (vWF) and vWF propetide
(vWFpp) characteristic for endothelial cell function
• Vascular endothelial growth factor, endothelin, caveo-
lin-1, asymmetric dimethylarginine, nitric oxide, and
circulating endothelial cells
• Markers of inflammation such as high-sensitivity C-
reactive protein (hs-CRP), interleukin-6, and other
cytokines or markers identified by “-omics” and flow
cytometry63.
Risk evaluation using a WoE approach for evaluation of
vascular toxicity must be based on detailed pathology assess-
ment including lesion distribution, if possible time course,
EM investigations to establish the NOAEL, and number of
species affected.  The hemodynamic status needs to be inves-
tigated, e.g. blood pressure, heart rate, possibly local flow
rates, vessel wall diameter and/or wall thickness, and other
biomarkers as appropriate and mentioned above.  Reversibil-
ity studies and mechanistic studies using an antagonist
against the suspected MoA (see above) may be helpful.  As
usual, pharmacokinetic data including area under the curve
(AUC) for unbound (free) drug concentrations and protein-
binding data are needed.  Theophylline, a well known anti-
asthma drug, is an example of a drug on the market with sig-
nificant vascular toxicity in laboratory animals, but after
many years of use it is clear that theophylline does not
adversely affect human vessels62.  Also autopsies of minoxi-
dil-treated patients did not reveal any evidence for cardio-
vascular side-effects.  However, it can not be excluded that
subtle drug-induced vascular adverse effects aggravate pre-
existing conditions such as atherosclerosis or potentiate the
effect of noxious stimuli such as tobacco consumption or
hypertension, or promote atherogenesis through a local
inflammatory cascade.  It may therefore be necessary to con-
duct studies in atherosclerotic animal models to check for
aggravation of the underlying disease by treatment with drug
candidates showing vascular APF.
If the MoA of the cardiovascular APF is known and
qualitatively relevant to man, the next question to address is:
Is the cardiovascular APF also quantitatively relevant under
therapeutic conditions applicable to man? Generally, a safety
ratio higher than 10 (ratio of the exposure of the most sensi-
tive and relevant animal species at the NOAEL over highest
therapeutic human exposure, see first part of this review) can
be considered to reflect safety.  Often and despite further
investigations the MoA and therefore the relevance of a vas-
cular APF for man are not known.  Then, considerations are
mainly limited to safety ratios in conjunction with indica-
tion, medical need, target population, and available alterna-
tives on the market.  Vascular toxicity continues to be a
significant safety issue for drug sponsors and regulators, as
in humans vasculitis can range from single organ involve-
ment, mostly the skin, to life-threatening multi-organ
vasculitis64.
Fig. 4. Subacute arteritis/periarteritis in a SIV 50 rat renal artery with
necrosis, inflammation, and proliferation of fibroblasts;
undisclosed drug. H&E, lens 25×.Ettlin, Kuroda, Plassmann et al. 219
Liver and kidney
Liver and kidney toxicity is relatively frequent and
often an issue during drug development65.  The liver is the
main site of the metabolism of xenobiotics including drugs
and expresses many cytochrome P450 isoforms.  The metab-
olism generally results in detoxification and excretion of
xenobiotics, but may occasionally also lead to a toxic inter-
mediate including e.g. short lived reactive oxygen species.
This toxification effect has been known for many years e.g.
for paracetamol, also called acetaminophen66.  Paracetamol
increases nitric oxide (NO), which scavenges superoxide
generated by reactive oxygen species to produce peroxyni-
trite.  This then causes protein nitration and tissue injury67.
The kidney is crucial for excretion of drugs from the
body and the urine concentration can pose a hazard to renal
tubuli and the associated tissue.  Rodents concentrate urine
to a much higher degree than man or dog, and local exposure
to toxic drugs or metabolites in the urine may therefore be
higher.  Oliguria in dehydrated patients, a frequent condition
in the elderly, can also be associated with high urinary con-
centrations of drugs and metabolites and therefore must be
regarded as a risk factor for adverse drug effects especially
on the kidney. 
Unless liver or kidney toxicity is chronic, it is usually
reversible.  Nevertheless, these toxicities can be serious in
the clinic: Patients, particularly the elderly, often also suffer
from a pre-existing liver or kidney disease, because of
enzyme induction or inhibition associated with the diet, with
alcohol or with concomitant drug therapy, or because of
genetic variances affecting e.g. drug metabolism68.  Preclin-
ical studies do not always allow detecting liver and kidney
toxicity69, though numerous and well established screening
methods exist, and liver and kidneys are extensively exam-
ined in toxicity studies.  Toxicogenomics may help to
improve detection of liver and kidney toxicity in preclinical
safety studies and provide biomarkers for human
monitoring70–73 .  The chances to elucidate the MoA of a drug
candidate with liver or kidney toxicity are relatively high,
because these toxicities are well studied.
Renal papillary necrosis is seen mostly in animals with
a range of drugs and chemicals74.  In man it is infrequent and
occurs mainly in conjunction with polypharmacy and preex-
isting renal diseases.  Of greatest concern are analgesics and
non-steroidal anti-inflammatory drugs (NSAIDs), which
inhibit cyclo-oxygenases and therefore inhibit the formation
of vasodilatory prostaglandins by papillary interstitial
cells75.  Renal papillary necrosis was reported also for
tyrosine kinase inhibitors and serotonin (5-HT1A) receptor
agonists76.  Recently, renal papillary antigen (RPA-1) was
proposed as biomarker to detect early renal papillary lesions
in rats77.  RPA-1 is an antibody to an unknown epitope of an
antigen in the rat renal papilla, specifically of the collecting
ducts.  The human equivalent of RPA-1 is not yet known77.
Overall renal papillary necrosis in laboratory animals treated
with a drug candidate is of clinical concern and needs careful
monitoring of the renal function in clinical studies.
Drugs interfering with the renal renin-angiotensin regu-
lation, such as inhibitors of the angiotensin-converting
enzyme or angiotensin II antagonists, can affect the kidney
in various ways including hypertrophy and hyperplasia of
the juxtaglomerular apparatus.  This finding is regarded as
exaggerated pharmacological effect78–80 and has also been
described in humans.  A number of agents, including drug
candidates, are known to induce α2μ globulin nephropathy
in male rats.  α2μ globulin is not found in significant
amounts or is completely absent in female rats, mice, guinea
pigs, dogs, monkeys, and humans.  Therefore, α2μ globulin
nephropathy is a species- and sex-specific finding without
relevance to humans81.
Although liver and kidneys are common target organs,
toxicity rarely leads to termination of drug development in
the preclinical phase.  Generally both toxicities can be mon-
itored in man with sensitive enzyme assays and potentially
toxic drug candidates can proceed with the necessary precau-
tions to clinical trials.  Recently the Predictive Safety Testing
Consortium has examined the issue of renal biomarkers in
urine82.  FDA and EMA (former EMEA) agreed that the fol-
lowing biomarkers qualify and are useful for detecting glom-
erular and/or tubular kidney toxicity in animals and partly
also in man: KIM 1 (kidney injury molecule-1), albumin,
CLU (clusterin), TFF3 (trefoil factor 3), total protein, cysta-
tin C, and β2-microglobulin82. 
The liver is the most common target organ in rodent
bioassays83.  Liver tumors are often due to an epigenetic
MoA, that is increased DNA replication.  Liver tumors are
often not relevant to man, but sustained liver toxicity and
regenerative proliferation is relevant to the evaluation of
human cancer risk84.  Increased cell proliferation (e.g. label-
ing index for DNA replication) and potentially associated
preneoplastic changes (e.g. liver weight increase, hepatocel-
lular necrosis or hypertrophy) can generally be detected in
subacute toxicity studies, e.g. in 13 week studies85. 
Gastro-intestinal tract
The tegaserod case:  Tegaserod, a 5HT4-receptor partial
agonist for the indication of irritable bowl syndrome, was
associated in the high dose group (600 mg/kg bw/day p.o.) of
the mouse lifetime bioassay with mucosal hyperplasia and an
increased incidence of adenocarcinomas in the small intes-
tine of 8 animals (7 in jejunum, 1 in ileum, affected sex not
stated)86.  The high dose corresponded to approximately 100
times the expected human exposure.  There was no evidence
of carcinogenicity at lower doses of up to approximately 35
times human exposure.  Mucosal hyperplasia was also found
in a subacute mice study after 2 weeks of 400 mg/kg bw/day
p.o.  Despite the relatively high safety ratio, the lesion was
investigated in detail, among other reasons because the irri-
table bowl syndrome is not life-threatening, though a highly
unpleasant disease to suffer from. 
The hypothesis that inhibition of the diamine oxidase
explained the MoA was not supported by the available data.
An involvement of 5-HT receptors could be excluded by fur-
ther experimental studies.  However, toxicogenomic investi-
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caused cellular stress most likely by increased gut peristaltic
movements.  Such stress may have triggered a proliferative
response in the intestinal mucosa, resulting in mucosal
hyperplasia following subacute treatment and tumors after
lifetime exposure.  The additional data also suggested that
the hyperplastic response was due to local tegaserod expo-
sure.  At the NOEL (150 mg/kg bw/day p.o. in mice) sys-
temic exposure (AUC) was 18-times higher than clinical
exposure in man and local gut exposure several 100-times
higher.  These exposure differences between animals and
humans were considered sufficient by the European Medi-
cines Agency (EMA) to conclude that the APF is of no con-
cern for the intended clinical use86.  The drug was on the
market, but was then withdrawn in a number of countries: In
clinical studies involving over 18,600 patients a very small,
but statistically significant increase in the incidence of car-
diovascular ischemic events (13 out of 11,614 patients with
tagaserod; 1 out of 7,031 with placebo) was seen.  The with-
drawal was requested by some health authorities, although,
according to press statements, apparently most patients with
CV adverse events had at least one CV risk factor or a pre-
existing cardiovascular disease. 
An unusual finding with a VEGF-receptor inhibitor:
The drug, a vascular endothelial growth factor (VEGF)
receptor inhibitor and inhibitor of angiogenesis in develop-
ment as anticancer drug, was without special findings in pre-
clinical studies up to 4 weeks duration.  During necropsies of
the 26-week rat toxicity study the duodenal diameter was
found increased in the high dose group (100 mg/kg bw/day
p.o.).  The histological evaluation of this study revealed epi-
thelial hyperplasia and infiltration of mucosal glands into the
lamina muscularis and partly into the peritoneum and gastric
wall at the high dose.  The lesion regressed, but did not dis-
appear following a 13 week recovery period.  Because of its
invasive behavior, the lesion was first diagnosed as being
malignant and clinical studies were put on hold 87.  Figure 5
shows the typical appearance with ectactic and partly hyper-
plastic glands infiltrating the deeper layers of the duodenal
wall. 
External preclinical experts had not seen a similar
lesion before, but considered it not to be malignant, also
because it regressed to some degree following termination of
exposure.  It was proposed to label the lesion as adenosis
with reversible hyperplasia.  Physiological differences of the
gastro-intestinal tract between rats and other species may be
responsible for the observed susceptibility of the rat: The
gastro-intestinal tract of rats continues to grow including fis-
sioning of crypts also after birth, a behavior not present in
mice, dogs or humans under non-pathological conditions.  In
fact, it could be shown that the lesion occurs only in rats, but
not in mice or dogs, and can therefore be considered to be
species-specific.  However, it was not possible to establish
the exact MoA of the drug candidate.  It also remained
unclear if the observed proliferation was a primary effect or
a secondary reactive event.  The hypothesis is that the drug
acts on mesenchymal components88, facilitating the down-
growth of epithelial cells into lower layers of the duodenal
wall.  In view of the indication in cancer treatment, clinical
trials, accompanied by careful monitoring of patients, were
considered to be ethically acceptable.  Additional preclinical
studies to further characterize the lesion were done, but the
results are not available to the public.  The drug candidate is
still in clinical development and well tolerated in humans. 
Phospholipidosis
Drug-induced phospholipidosis (PLD) is a storage dis-
ease characterized by lysosomal accumulation of polar lip-
ids, visible at microscopic level as intracellular inclusion
bodies and in the EM as concentrically lamellar bodies89, 90.
Typically it is a consequence of treatment with cationic
Fig. 5. Adenosis in the duodenum of a Wistar rat after a 26 week oral
treatment with 100 mg/kg bw/day of a VEGF-receptor
inhibitor. H&E, lens 10×.
Fig. 6. Phospholipidosis with foam cells in lungs of a SIV 50 rat
following 16 daily oral doses of 40 mg/kg bw/day of
chlorphentermine. H&E, lens 25×.Ettlin, Kuroda, Plassmann et al. 221
amphiphilic drugs and seen in cells with high membrane
turnover, such as macrophages, or in tissues with high lipid
or phospholipid biosynthesis such as adrenals, retina or lung.
Figure 6 shows an example of phospholipidosis following 16
daily doses of chlorphentermine, an appetite suppressor drug
now withdrawn from the market for other reasons. 
Occurrence and severity vary between species, strain,
and age of laboratory animals.  Often a number of organs is
affected.  It can take just a few doses or many months of
treatment to induce PLD.  PLD, if not associated with sec-
ondary reactions, generally resolves, but this may take con-
siderable time.  PLD must be distinguished from lipidoses91.
Despite extensive PLD, laboratory animals generally seem
to be well.  However, effects on cell function are possible92,
93 and include impairment of cell metabolism or of pino/
endocytosis.  Some drugs such as propranolol and verapamil
were reported to lead to lactate dehydrogenase (LDH)
release from hepatocytes, while other drugs, such as chloro-
quine and amiodarone, may be associated with myopathy.
Some authors 94 distinguish between different types of
PLD.  Macrophage-dominant PLD is characterized by
foamy, enlarged macrophages in lungs, particularly in the
subpleural area, and in lymphnodes, but also in liver, spleen,
thymus and/or bone marrow.  In the parenchymal cell-domi-
nant PLD phospholipids accumulate in hepatocytes, renal
and bile duct epithelia, endocrine cells, striated, and smooth
muscle cells, endothelial cells and/or nerve cells.  Localized
PLD is a special type of parenchymal form and probably
reflects exposure of the affected organ to a higher concentra-
tion of the drug.  Possible mechanisms of phospholipid accu-
mulation are inhibition of lysosomal phospholipase activity,
altered phospholipid biosynthesis and/or impaired delivery
of phospholipid degrading enzymes to lysosomes.
The occurrence of PLD in preclinical studies is always
troublesome, though it is not the end for a drug candidate.
PLD inducers are often effective drugs, as their lipophilicity
facilitates permeability into various tissues.  Screening for
PLD potential is possible e.g. based on the physicochemical
properties of the drug candidate, quantitative structural
activity relationship (QSAR) modeling, and using in vitro
screens with flow cytometry or in vivo studies followed by
EM95.  More recently, also toxicogenomic investigations
were used as screening tool96.  Risk evaluation of PLD
inducing drug candidates needs to take into account all rele-
vant factors from preclinical studies including degree of
PLD, progression, reversibility, functional effects, and site
of accumulation.  PLD in non-regenerative tissues such as
the nervous system increases concern.  Other aspects to be
considered during the WoE analysis are the number of spe-
cies affected, the availability of biomarkers, and of course
safety ratios.  However, as PLD in laboratory animals may
not be predictive for man, further development is not
excluded even in case of a potentially insufficient safety
ratio, depending mainly upon the indication of the drug can-
didate.  More caution is recommended in case of indications
needing treatment over longer periods of time.  Monitoring
for PLD in clinical studies is possible e.g. by examining
peripheral white blood cells, especially lymphocytes, for
lysosomal lamellar bodies by EM or flow cytometry.  How-
ever, the relationship between tissue burden by PLD and
appearance of lysosomal lamellar bodies in lymphocytes is
not well known.  Also Nile Red coloration can be used to
show lymphocyte lipid inclusions.  Urinary bis-monoglyc-
erol phosphate (BMD) was reported to correlate with PLD,
at least in rats97.  For a recent overview of possible strategies
to develop drug candidates with a potential for inducing PLD
see also95.
Partly subtle lesions
It is easy to miss subtle lesions in early preclinical
safety studies.  If picked up, the question always is: Is it just
a stone in the desert (incidental finding) or is it the tip of a
pyramid buried under sand (significant problem)? MEK
inhibitors are developed as anticancer drugs.  The name
MEK is derived from a combination of MAPK/ERK kinase,
where MAPK (MAPK1) stands for mitogen-activated pro-
tein kinase 1 and ERK (ERK2) for extracellular signal-regu-
lated kinase 2.  MEK inhibitors are now known to be
associated with multifocal mineralization in different
tissues98, in particular also in the gastric mucosa of rats,
already 15 days after a single dose of 500 μmol/kg99.  The
mineralizations are partly preceded by increased plasma lev-
els of 1,25-dihydroxyvitamin D and hyperphosphatemia.
MEK is involved in the vitamin D-induced transcriptional
activation of the cytochrome P450C24 (CYP-24) promoter.
The induced CYP-24 is responsible for degradation of active
vitamin D3 metabolites.  If MEK is inhibited, vitamin D is
no longer inactivated100.  Vitamin D metabolism differs
between humans and rats101.  Furthermore only minor miner-
alization is seen in dogs and monkeys.  Therefore rodents
may not be predictive for this type of adverse effect in man:
So far, clinical administration of MEK inhibitors was not
found to be associated with metastatic mineralization.  How-
ever, measurement of plasma calcium, phosphorus, and
other electrolytes is recommended at least during early clin-
ical trials and during trials of longer duration. 
Metastatic mineralization can also be caused by a MoA
associated with hypercalcemia, e.g. increased secretion of
parathyroid hormone in case of parathyroid tumors leading
to bone resorption.  Similarly, destruction of bone by pri-
mary tumors such as multiple myeloma or by extended skel-
etal metastasis, vitamin D intoxication or renal failure with
secondary hyperparathyroidism through retention of phos-
phate can lead to mineralized foci. 
Hypertrophic osteopathy
The following bone lesion was not interpretable at the
time it was detected.  As follow-up drug candidates were
available, the involved drug candidate, an isoquinoline
derivative with bronchodilating anti-inflammatory activity
through inhibition of PDE IV, was not further developed.
The lesion was first seen in a reproductive study, where the
male rats were treated for up to 15 weeks and the females for
up to 7 weeks with SDZ MNS 949 (6,7-dimethoxy-3-222 Adverse Preclinical Findings—2
methyl-1-[3',5'-bis (methoxyethoxy) phenyl-isoquinoline).
At the high dose of 130 mg/kg bw/day in feed, swollen legs
were seen in around 40% of rats of both sexes.  Histologi-
cally males showed hyperostosis in the distal part of the tib-
ias and/or a bony shell formation arranged in a peripheral
circle, partly interspersed with fat marrow.  About half of the
females had the same changes, while the other half showed a
high grade of chondrogenesis with an inflammatory compo-
nent as illustrated in Fig. 7.  Some animals also had hyperos-
tosis of the tail root vertebrae.
These lesions were further characterized in an addi-
tional 26 week study102.  Hypertrophic osteopathies are
known to occur in various species, generally as a conse-
quence of other diseases including intrathoracic neoplasias.
Release of vasodilating endogenous substances is likely to
be involved in the pathogenesis.  Vasodilation could also
have played a major role in the lesions described here.  It was
assumed that the process begins with an inflammation initi-
ating chondrogenesis, which in turn leads to hyperostosis
with shell formation. 
PPAR agonists
APFs with PPAR agonists are a much debated issue
these days103–105.  PPAR stands for peroxisome proliferator-
activated receptors, which are nuclear hormone receptors
acting as ligand-activated transcription factors.  Commonly
three subtypes are distinguished: α (alpha), δ (delta, some-
times also called β beta) and γ (gamma).  α receptors are
mainly involved in fatty acid oxidation in livers and muscles
during the fasting response.  δ receptors are important for
fatty acid oxidation and energy uncoupling in fat tissue and
muscles.  γ receptors play a role in lipogenesis and lipid stor-
age in livers and fat tissues as well as in the regulation of
insulin sensitivity of the muscles106, 107.  PPAR α agonists
such as fibrates improve dyslipidemia, while PPAR γ ago-
nists such as thiazolidinediones improve insulin resistance
and therefore diabetes mellitus.  The complementary action
of PPAR α and γ agonists is beneficial for patients suffering
from metabolic syndrome and renders the development of
dual PPAR α/γ agonists attractive in spite of safety
concerns108.
Besides drugs, other compounds such as phthalate ester
plasticizers, pesticides, and industrial solvents are known to
increase size and number of peroxisomes in laboratory
animals109.  Peroxisome proliferation under exposure to
these compounds is generally most marked in rats and mice,
less in hamsters, and only slightly, if at all, in guinea pigs,
monkeys, and humans.  Less than half of the over 100 known
peroxisome proliferating compounds were tested in rodent
bioassays and shown to be carcinogenic primarily in livers
by activation of the α receptor.  It is unlikely that older com-
pounds such as clofibrate110 are hepatocarcinogens at
expected levels of exposure of humans.
However, PPAR α is also present in human cells,
though at much lower concentrations, and the data do not
permit to exclude that the animal MoA is plausible in
humans111.  Events in rodent livers are activation of PPAR α,
peroxisome proliferation with increased acyl-CoA oxidase,
and microsomal fatty acid oxidation resulting in excessive
production of hydrogen peroxide, Kupffer-cell-mediated
events, interference with cell proliferation, and apoptosis of
hepatocytes as well as selective clonal hepatocyte expansion.
PPAR α agonists may also affect other organs such as the
testis111: The MoA in rat LC also involves PPAR α activa-
tion in the liver, resulting in changes of the metabolism of
LC relevant hormones and their precursors.  Testicular test-
osterone biosynthesis may also be directly inhibited.  Simi-
larly, proliferative changes in rat pancreatic acinar cells start
with PPAR α activation in the liver and are associated with
changes in the bile synthesis and composition.  Today’s
PPAR α agonists in development are 10–1000 fold more
potent human PPAR α agonists than traditional fibrates, and
humans are often significantly more sensitive to their phar-
macological action than rodents112.  These new facts change
the toxicological assessment of modern PPARs fundamen-
tally. 
PPAR agonists submitted to date are not genotoxic in
the standard ICH genotoxicity battery, but are carcinogenic
in various rodent species and strains, in both sexes, and var-
ious organs.  In particular the following tumors can be
observed with PPAR γ and α/γ dual agonists: Hemangiosar-
comas in mice, urothelial bladder tumors particularly in male
rats, adipose tissue tumors in rats, liver tumors particularly in
female mice, cervix and gall bladder tumors in mice and
stomach tumors in male rats106.  Therefore PPAR agonists
are classified as “probable human carcinogens” according to
the criteria of the Environmental Protection Agency (EPA)
and the International Agency for Research on Cancer
(IARC).  Further adverse effects seen in humans and partly
also in laboratory animals are signs of myopathy and rhab-
domyolysis, weight gain, fluid retention, peripheral edema,
and potentially increased risk of cardiac failure108.  Never-
theless, PPAR agonists are promising drugs.  Risk evaluation
Fig. 7. Hypertrophic osteopathy in a female Wistar rat treated orally
for 47 days with 130 mg/kg bw/day of the PDE IV inhibitor
SDZ MNS 949. H&E, lens 10×.Ettlin, Kuroda, Plassmann et al. 223
must be done for each adverse effect separately and case-by-
case. 
For starting clinical trials in man FDA’s recommenda-
tions are consistent with those of other regulatory authorities
and include113: For clinical trials exceeding 6 months dura-
tion preliminary results from rodent bioassays are needed.
Transgenic mouse models are not accepted.  If animal
tumors are observed, mechanistic data are welcome.  If
rodent tumors occur only at exposures above the 10-fold
therapeutic exposures at the maximal recommended human
dose (MRHD), phase 3 studies over 6 months are approved,
provided that the receptor transactivation potency in animals
and humans is comparable.  If rodent tumors occur at lower
exposure or if for toxicity reasons doses leading to exposure
levels in excess of the 10 times human exposure levels at the
MRHD are not possible, the review will occur on a case-by-
case basis113.
The following example serves as illustration for the risk
assessment process of a PPAR agonist, namely the dual
PPAR α/γ agonist muraglitazar114.  Two-year studies were
conducted in mice with doses of 1, 5, 20, and 40 mg/kg bw/
day and in rats with doses of 1, 5, 30, and 50 mg/kg bw/day.
Gallbladder mucosal hyperplasia and some benign gallblad-
der adenomas were observed in male mice at the two higher
doses corresponding to over 60 times the area-under-the-
curve (AUC) at human exposure with daily doses of 5 mg.
The incidence of transitional cell papilloma and carcinoma
of the urinary bladder in male rats was increased in a dose-
related fashion starting at 5 mg/kg bw/day corresponding to
approximately 8 times the human therapeutic AUC and was
mediated by urolithiasis.  Incidences of subcutaneous liposa-
rcoma in male rats and subcutaneous lipoma in female rats
were increased at the high dose only corresponding to
approximately 50 times the human therapeutic exposure at 5
mg/day.  These mesenchymal tumors were attributed to per-
sistent pharmacologic stimulation of preadipocytes, leading
also to hyperplastic and metaplastic adipocytes in mice and
rats.  Relevant non-neoplastic changes consisted of thinning
of cortical bone in mice.  As muraglitazar is not genotoxic,
the authors concluded that the observed tumorigenic effects
in mice and rats have no clinical relevance, since they
occurred at either clinically not relevant exposures (gallblad-
der and adipose tumors) or by a species-specific MoA (uri-
nary bladder tumors).
In 2005, the Health and Environmental Sciences Insti-
tute (HESI) PPAR Agonist Project Committee was estab-
lished by pharmaceutical companies in an effort to better
understand the MoA and human relevance of rodent tumors
induced by PPAR agonists115.  The working group concluded
that the most likely MoA for vascular tumors including the
mesenchymal component in mice and hamsters, with mice
being also predisposed to spontaneous development of
hemangiosarcoma, is stimulation of adipogenesis with sub-
sequent release of cytokines and growth factors leading to
mesenchymal and/or endothelial cell proliferation and
neoplasia116.  This hypothesis is based on the following
observations:
• Adipocytes are an important source of cytokines and
growth factors
• Adipogenesis and angiogenesis are linked
• PPAR γ agonists induce hemangiosarcomas primarily
in adipose tissue
While some of the above factors and events may also
play a role for the induction of sarcomas in rats, a specific
MoA has so far not been proven for this species.  Stimulation
of DNA synthesis in subcutaneous adipose tissues of rats
treated with the dual PPAR α/γ agonist tesaglitazar is not
mediated via activation of PPAR receptors in these cells, but
may involve proliferation of undifferentiated mesenchymal
cells in subcutaneous tissues117. 
Another prominent feature of PPAR γ and dual α/γ ago-
nists in rodent carcinogenicity studies is the occurrence of
urinary bladder carcinomas118.  Urolithiasis was identified as
the inciting event in the MoA due to urinary changes119.
Demonstration of urinary solids following PPAR agonists
treatment has not always been possible, but this is likely due
to methodological issues120.  Abnormal crystalluria or calcu-
lus formation does not occur in humans in response to PPAR
agonists.  Lesions were also reported in the monkey urothe-
lium, but the pathology working group of the HESI PPAR
Agonist Project Committee ascertained that the suspect find-
ings were normal in the monkey urothelium and epithelial
hyperplasia was absent121.
PPAR α agonists are also known to induce muscle
lesions, both in animals and in humans122.  In animals edema
and striated skeletal muscle fiber lesions are found.  In
humans fibrate treatment can be associated with myalgias
and more rarely rhabdomyolysis, notably in combination
treatment with statins123.  Such adverse findings are more
likely with gemfibrozil than e.g. with fenofibrate and can be
monitored using CK and AST levels.  The MoA is unclear,
but may also involve effects on kidneys with increased blood
volume and aldosterone48.  Of particular concern are cardiac
effects which can be monitored in man using troponin levels.
To cover the latter issue, the FDA has published a draft guid-
ance in 2008 for development of diabetes drugs124.  Muscle
lesions must be considered to be relevant to man and suffi-
cient safety ratios are needed to proceed with development
of drug candidate in man.
In conclusion, PPAR α and dual α/γ ligands are in
widespread clinical use for the treatment of dyslipidemia and
insulin resistance and in future may also be used as anti-
inflammatory drugs.  When involved in the development of
PPAR agonists, one has to be prepared to solve a number of
issues.  The carcinogenic alert increases with an increasing
number of positive parameters as listed below:
• The increase in tumor incidence is dose-related and
well above the control range
• Tumors occur at much younger age than in the controls 
• There is a shift to less differentiated tumors, possibly
with impact on survival
• Tumors are associated with an early increase in preneo-
plastic lesions
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needs to be decided on a case-by-case basis
Genotoxicity
For reasons of simplicity genotoxicity and mutagenicity
are subsequently summarized under the heading of genotox-
icity, as this term also covers mutagenicity.  The area is dis-
cussed only to the extent the informed general toxicologist
and toxicologic pathologist should be familiar with.  If sig-
nificant issues arise in this area, it is advisable to consult
with a specialized colleague.  In case of a genotoxicity or
carcinogenicity issue it is good to remember that one third of
the drugs listed in Physicians’ Desk Reference PDR18 have
positive or equivocal genotoxicity or carcinogenicity results
(for details see below).  Two-thirds of compounds positive
for genotoxicity, particularly those positive in in vitro mam-
malian cell assays only, act in rodent bioassays by epigenetic
mechanisms.
In their update on genotoxicity and carcinogenicity test-
ing of marketed pharmaceuticals Brambilla and Martelli
recently reported the follwing findings125: Of 838 drugs used
for continuous therapy of at least 6 months or intermittently
over extended periods, 366 (43.7%) did not have retrievable
genotoxicity or carcinogenicity data.  For the remaining 472
(56.3%) at least one genotoxicity or carcinogenicity test
result was available, but only 208 drugs (24.8%) had all data
required by current guidelines.  Of 449 drugs with at least
one genotoxicity test, 183 (40.8%) had at least one positive
finding.  Of the 338 drugs with at least one carcinogenicity
test, 160 (47.3%) showed at least one positive result.  Of 315
drugs with both genotoxicity and carcinogenicity data, 116
(36.8%) are neither genotoxic nor carcinogenic, 50 (15.9%)
are not carcinogenic but positive in at least one genotoxicity
assay, 75 (23.8%) are carcinogenic in at least one sex of mice
or rats but negative in genotoxicity assays, while 74 (23.5%)
are both genotoxic and carcinogenic. 
Similar findings were published in 2001 for 467 mar-
keted drugs, which were partly for short-term use only126.
Anticancer drugs, nucleosides, steroids, biologicals, and
peptide-based drugs were excluded from the analysis,
because they are genotoxic by their MoA (anticancer and
steroid drugs), and/or interfere with bacterial tests (nucleo-
sides, biologics including peptide-like drugs), and are there-
fore generally not tested for genotoxicity.  Where test results
were available, bacterial mutagenesis assays were positive in
8.3%, in vitro cytogenetic tests in 24.8%, the mouse lym-
phoma assay (MLA) in 25%, and in vivo cytogenetic tests in
11.5%.  Among the various tests the sister chromatid
exchange assay (SCE) had the largest percentage of positives
(43.5%) and mammalian mutagenesis assays (excluding
MLA) the lowest (2.2%).  Obviously, the predictive value of
genotoxicity findings for two year bioassay outcomes is lim-
ited, since carcinogenicity can occur also via non-genotoxic
mechanisms.  The authors concluded that no combination of
genotoxicity assays was superior in predicting rodent car-
cinogenesis bioassay results than the bacterial mutagenicity
test alone.  Similar results were also published later127.  Fur-
ther analyses of published genotoxicity and carcinogenicity
data are also available for analgesics, anti-inflammatory
drugs, and antipyretics128 as well as for other classes of com-
pounds.
Entacapone, a COMT inhibitor used as adjunct to
levodopa and dopa decarboxylase (DDC) inhibitors for treat-
ment of Parkinson’s disease, is an example of a drug on the
market with both in vitro genotoxicity and in vivo rat
carcinogenicity129.  The MLA was found to be positive at
concentrations of 25–50 μg/ml.  The most likely reason is
chromosome damage as also suggested by the chromosomal
aberration test in human lymphocytes: It was positive with
S-9 mix at concentrations of 100 μg/ml and showed also
increased numbers of aberrant cells at 400 μg/ml.  Ames
tests, the in vitro DNA binding study, the in vivo micronu-
cleus test and the rat liver UDS test were negative.  Entaca-
pone caused also renal adenomas and carcinomas in males at
the high dose (400 mg/kg) in the two year rat study, while the
mouse study did not allow adequate conclusions due to a
high incidence of premature mortality at the high dose.
Chromosome damage in vitro only was not regarded as
impediment to market the drug.  In addition, the renal neo-
plastic findings appeared to be due to nephrotoxicity seen in
a one year toxicity study in male rats only, at plasma levels
20 times higher than those seen in man.  The carcinogenic
potential of entacapone administered in combination with
carbidopa-levodopa has not been evaluated.
Positive genotoxicity results must be scrutinized.  Rea-
sons for false positive Ames tests can be an over-induction of
phase 1 metabolism with increased activation of drug candi-
dates to genotoxic metabolites, or a lack of or insufficient
induction of phase 2 metabolism responsible for deactivation
of genotoxic drug metabolites.  Dose-dependent and repro-
ducible in vitro but negative in vivo tests can indicate that in
vivo no genotoxic products are formed, or that such geno-
toxic products are inactivated or do not reach the target cell.
A positive Ames test and a positive chromosome aberration
test in human lymphocytes indicate a critical, but not hope-
less situation, particularly if the chromosome aberration test
is only positive at toxic concentrations, which are known to
induce apoptosis and release of endonucleases leading to
chromosome aberrations and micronuclei in vitro.
No further testing for genotoxicity is generally needed
if a statistically significant positive response is still within
the historical negative control range or the positive response
is observed only at the high dose and only under one experi-
mental condition, but is not reproducible under equivalent or
similar experimental conditions for the same endpoint.  In
vitro mammalian cell assays are frequently positive, particu-
larly under non-physiological culture conditions such as
high osmolarity or low pH.  A positive micronucleus test is
relevant if the positivity is due to a clastogenic effect.  How-
ever, if the positive result is attributable to aneuploidy, the
genotoxic risk is considered to be negligible.  This is also
true for clastogenic effects due to an interaction of the xeno-
biotic with proteins, such as topoisomerase, because such
interactions have a threshold.  If there is insufficient WoE to
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as not relevant to man, additional genotoxicity studies are
indicated.  Such studies can be done either in vitro to provide
mechanistic information and/or in vivo generally on different
tissues. 
The ICH step 2 2008 draft consensus guideline “Guid-
ance on genotoxicity testing and data interpretation for phar-
maceuticals intended for human use S2(R1)”130 is to replace
the older S2A and S2B guidelines mainly for the following
reasons:
• High rate of irrelevant positive findings in in vitro
mammalian cell tests
• Integration of newer test methods, in particular the in
vitro micronucleus test, in vivo models in a variety of
tissues, e.g. by using the single cell gel electrophoresis
(Comet) assay or transgenic animals, and the use of rat
blood for micronucleus evaluation
• Efforts for further improvement of animal welfare
Table 3 summarizes the new genotoxicity test strategy
proposed in the 2008 draft consensus guideline.
Further genotoxicity testing in case of positive or equiv-
ocal findings in standard genotoxicity tests may also include
• Genotoxicity markers from longer-term studies
° Micronucleated normochromatic erythrocytes from
mouse blood
° Metaphase analysis of cultured blood lymphocytes
from rat or monkey 
• Analysis of DNA adducts
• Comet assay
• Transgenic mouse mutation assay
• Short-term carcinogenicity study e.g. using p53 +/–
transgenic (knockout) mice, particularly if there is
residual concern that genotoxic activity may contribute
to tumorigenesis.  This test is sometimes requested by
certain regulatory authorities prior to repeat-dose clini-
cal trials 131, but it is not universally accepted. 
A potential alternative is the rasH2 model, considered
to be appropriate for testing of genotoxic and non-geno-
toxic compounds and accepted as alternative to two-
year mouse carcinogenicity studies by the U.S. Food
and Drug Administration, the Japanese Ministry of
Health, Labor, and Welfare, and the EMA for regula-
tory submission132–137.  “Short-term” 26 week bioassays
with transgenic mice may permit a more timely assess-
ment of the carcinogenic potential of drug candidates
before starting long-term clinical trials138.
A further test option—though at present not well
accepted, at least not in Japan—is examining peripheral
blood lymphocytes for micronuclei from humans in clinical
trials139.  Peripheral blood lymphocytes do not divide and
have a low capacity for DNA repair.  As DNA damage is not
lethal in resting lymphocytes, the damage accumulates and is
expressed e.g. as micronuclei following stimulation to divide
in vitro. 
Moreover, cell transformation assays, e.g. on Syrian
hamster embryo cells, are sometimes mentioned as test
options and may be requested by certain regulatory
authorities131.  The test may be used to generate additional
data, but the molecular basis of cell transformation is not
well understood.  In particular, the relationship between
genotoxicity and transformation remains unclear.  Therefore,
the results of cell transformation assays may be difficult to
interpret.
Hazard characterization based on genotoxicity results
must include among others the following aspects: Type and
number of tests with positive results, reproducibility, dose-
response relationship, consideration of cytotoxicity for a
positive outcome, magnitude of the positive result.  Particu-
larly, if a repeat test with a new batch turns out positive, the
possibility of a contamination with by-products must be con-
sidered.  For the final risk evaluation of genotoxicity and car-
Table 3. ICH Guidance on Genotoxicity Testing130
Current (S2B) Revised (S2[R1])
Option 1 Option 2
Bacterial gene mutation Bacterial gene mutation Bacterial gene mutation
(with repeat) (no repeat) (no repeat)
In vitro mammalian cell test: In vitro mammalian cell test: NO in vitro assay in mammalian cells
Chromosome aberrations Chromosome aberrations
or mouse lymphoma assay or mouse lymphoma assay
or micronucleus assay
at 10 mM top concentration  at 1 mM top concentration 
or over 50 (80*) % cytoxicity or at most 50 (80*) % cyototoxicity
In vivo micronucleus test In vivo micronucleus test In vivo micronucleus test plus
2nd in vivo endpoint or tissue 
stand alone test preferably integrated into preferably integrated into
rodent toxicity study rodent toxicity study
* Relative total growth in case of mouse lymphoma assay.226 Adverse Preclinical Findings—2
cinogenicity, the following factors are of particular
importance131:
• Experimental data generated during genotoxicity, gen-
eral toxicity, and rodent bioassay studies, ADME
parameters as well as pharmacology data of the drug in
question
• Drug indication: Hard vs. soft indications, as higher
treatment-related risks are more acceptable for severe
life-saving indications than for relatively harmless sick-
nesses
• Target population, in particular the age of the targeted
patient population
• Duration of treatment: Single, multiple or long-term.  In
general, single-dose clinical studies are permitted
regardless of the genotoxicity results (see also next
paragraph)
• Importance of the drug: Are there alternatives and what
are the additional benefits offered by the drug in ques-
tion
It may not be possible to eliminate all impurities in a
drug substance140.  A staged threshold of toxicological con-
cern (TTC) analysis is then a pragmatic approach to balance
duration of clinical trials, availability of analytical methods,
maturity of synthetic schemes, and the potential risk to
humans.  Toxicological concerns can be addressed e.g. by
controlling daily intake.  The acceptable daily intake of
genotoxic substances varies between approximately 1.5 μm/
day for long-term (“lifetime”) intake and approximately 60
μm/day for treatments of up to 1 month.  Based on scientific
reasoning, these virtually safe intake values do not pose an
unacceptable risk to either human volunteers or patients at
any stage of clinical development and marketing of a phar-
maceutical product141.  The limit of 1.5 μm/day for lifetime
intake is also mentioned in the EMA “Guideline on the limits
of genotoxic impurities”142 and in the FDA draft guideline
“Guidance for industry.  Genotoxic and carcinogenic impu-
rities in drug substances and products: Recommended
approaches”143. 
Experimental safety data from animals are superseded
by clinical data obtained in man.  However, clinical data on
genotoxicity and carcinogenicity are difficult or impossible
to obtain and weak effects are likely to go unnoticed.  Geno-
toxicity and carcinogenicity effects are considered to be
essentially irreversible.  Therefore, preclinical data on geno-
toxicity and carcinogenicity retain their value even for drugs
on the market.  Only long-term well-controlled epidemiolog-
ical studies on large cohorts of patients would have more
weight than preclinical data, but such studies are potentially
unethical, difficult, and resource-intensive to conduct and
are therefore generally not available.  This needs to be taken
into account during the risk evaluation process.
Reactions to positive genotoxicity data may differ
between different regulatory divisions and agencies.  For
clinical trials, particularly in hard indications, that is in
severe, potentially life-saving indications, genotoxicity may
be acceptable, but the risk for healthy volunteers must be
minimal, as explained above.  If questionable genotoxicity is
observed, development of the drug candidate generally pro-
ceeds, though, if in the later lifetime bioassays questionable
tumor findings are present, the situation may become diffi-
cult depending on the indication of the drug, the patient pop-
ulation, and available alternatives (but see also the
entacapone case summarized above).  In case of a strong
genotoxicity signal in the absence of good evidence that the
result is not relevant to man, it is wise to stop development,
unless the drug is for a hard indication such as cancer treat-
ment.  With few exceptions a “No go” situation arises, if
genotoxicity is observed in vitro and in one in vivo test, and
(potentially) treatment-related tumors occur in rodent bioas-
says which may be relevant to man.  The situation is even
more serious if precursor lesions are already present in
shorter-term studies.  However, one should not forget that
the widely used over-the-counter drug paracetamol tests pos-
itive in the chromosome aberration test in lymphocytes and
mouse bone marrow cells and leads to DNA adducts, while
Ames and V79 micronucleus tests are negative 144.  In addi-
tion, at high doses paracetamol induces liver and bladder
tumors in rodents.  However, these doses cause hepatotoxi-
city, which is a plausible explanation for the liver tumors,
and the urinary bladder tumors are likely to be due to uroli-
thiasis 145.  Available data suggest three possible MoA for
paracetamol-induced genotoxicity: (1) Inhibition of ribonu-
cleotide reductase; (2) increase in cytosolic and intranuclear
Ca2+ levels; (3) DNA damage caused by N-acetyl-p-benzo-
quinone imine (NAPQI) after glutathione depletion 145.  All
MoA have thresholds, and genotoxic effects of paracetamol
appear only at dosages toxic to the bone marrow and not
achieved at therapeutic dosages.
Reproductive toxicity
As said above regarding genotoxicity, also reproductive
toxicity is discussed here only to the extent to which the
informed general toxicologist and toxicologic pathologist
should be familiar with.  If significant reproductive toxicity
issues arise, a specialized colleague should be involved.
Reproductive toxicity studies serve to test for adverse effects
on the following parameters146, 147.
• Fertility of both sexes, estrus cycle and tubal transport
in females, implantation and development of pre-
implantation stages of the embryo, as well as functional
effects on mating behavior in both sexes and epididy-
mal sperm maturation in males
• Pregnancy and development of the embryo and fetus to
detect embryotoxicity and/or teratogenicity, which may
be expressed as increased occurrence of resorptions,
abortions, stillbirth, malformations, gender distribution
of the pups, and effects on fetal weight 
• Pregnancy, parturition, lactation, pre-natal embryo-
fetal, and peri- and post-natal development of the off-
spring until sexual maturity 
Alternatives to the conventional reproductive toxicity
tests are still under evaluation148.
Reproductive toxicity is a highly sensitive issue.  The
assessment of adverse effects on fertility depends to someEttlin, Kuroda, Plassmann et al. 227
degree on the affected sex: Recovery of spermatogenic tox-
icity is possible as long as spermatogonia type A survive.
However, there is no oocyte regeneration: Oocyte destruc-
tion permanently reduces the number of oocytes available.
Absence of oocytes means permanent female infertility, sim-
ilar to menopause initiated in humans by exhaustion of avail-
able oocytes.  Adverse fertility effects of a drug candidate
have consequences for the further development of that drug
depending on targeted patient population, indication, and
available alternatives.  Collection of human data for the
assessment of preclinical findings is possible to a limited
extent in men by sperm analysis and in women by observa-
tion of the menstrual cycle. 
Embryotoxicity and particularly teratogenicity are seri-
ous findings.  If unequivocal embryotoxic or teratogenic
effects are seen in animal species as e.g. with endothelin
antagonists149, safety ratios are generally not helpful: It is
rarely possible to establish the MoA and our understanding
of these types of APF is generally too limited to allow
extrapolation of such animal data to humans.  Such findings
always lead to a contraindication to the effect that women in
child-bearing age can only be treated if not pregnant and if
under reliable contraceptive treatment.  In case of pregnancy,
the potential benefits of treatment of the expecting mother
must outweigh the potential risks to the fetus (see below).
Whether the drug is viable depends on scientific judgment,
marketing prospects, legal aspects because of possible dam-
age claims and the company strategy. 
Teratogenicity in animals is regarded as being predic-
tive to man with the exception of cortisone-induced cleft pal-
ates in mice, a species known to be particularly sensitive to
cortisone during pregnancy150, 151.  Questionable findings
potentially indicating embryotoxicity and/or teratogenicity
need to be assessed in more detail, e.g. by investigating if the
observed effect is reproducible and/or in case of embryotox-
icity reversible.  A potential embroytoxic or teratogenic
effect also needs to be distinguished from retardation of
development as e.g. associated with maternal toxicity, as
well as from artifacts or natural variation.  For drugs that
may have developmental toxicity in humans, a careful risk
management and mitigation strategy needs to be imple-
mented for clinical trials and later for marketing.
Particularly delicate, but not that rare, are potentially
teratogenic findings in the high dose group, such as isolated
malformations in some fetuses from single litters.  A good
historical database and absence of a broader teratogenic pat-
tern of the observed malformations help in risk evaluation,
which also needs to take other findings such as maternal
observations into account.  Data from the literature or other
sources about the finding and possibly about the drug class
have to be reviewed and experts to be involved as needed.
The findings should be discussed with regulators.  Addi-
tional studies may be warranted case-by-case to conclude the
integrative assessment. 
Regulators classify the fetal risk of drugs, but there are
some differences in the criteria used by different countries.
The Food and Drug Administration FDA categories and their
criteria152 are shown in Table 4.  They can be found in detail
in the Code of Federal Regulations Title 21, Part 201 -
Labeling - Subpart B153.
Another example for pregnancy categorization is e.g.
the Australian categorization, which is partly more
detailed154.  There is no official categorization of drug risks
to the fetus in Japan, but the information about fetal risk is
described in the package insert.
Reliable human data are generally missing and there-
fore only few drugs can be assigned to the category with
least concern for teratogenicity (category A of the FDA clas-
sification).  When faced with a therapeutic decision for a
woman at child-bearing age, the treating physician may
often not find it easy to select the optimal drug based on the
available classification.  Therefore, FDA is currently propos-
ing to amend this regulation and to require that labeling
includes a summary of the risks of using a drug during preg-
nancy and lactation: A discussion of the data together with
the relevant clinical information supporting that summary
will be requested.  The proposal would eliminate the current
categories A, B, C, D, and X155.  Various reference guides for
and epidemiological studies about the use of drugs in preg-
nancy and lactation are published156–160.
Effects on pre-, peri-, and post-natal fetal development
including parturition and lactation need to be investigated as
to the possible underlying pathogenesis and reversibility.
The MoA is often not known and, unless it is not relevant to
humans for obvious reasons, knowledge of the MoA is also
not very helpful in contrast to a sufficiently high safety ratio. 
In summary: Embryotoxicity and teratogenicity do not
result in termination of the development of a drug, but lead
to modifications of its use, that is to restrictions such as
exclusion of women in child-bearing age without contracep-
tive therapy and the exclusion of pregnant women, particu-
larly during the first trimester, and limitation to hard
indications for treatment of the aforementioned patient pop-
ulation.  Adverse fertility effects and delayed, but reversible
fetal development may be handled similarly to general toxic-
ity findings. 
Conclusions
Toxicologists and toxicologic pathologists need to be
prepared to deal with APFs.  Toxicity and carcinogenicity
studies are designed more for sensitivity (avoiding false neg-
ative results, that is missing toxicity) than for specificity
(avoiding false positive results).  Unexpected APFs are fre-
quent, if not the rule, when testing potent drugs.  To resolve
significant issues, experts should be asked to join a working
group specifically constituted for addressing the APF issue
in question.  This working group should be an integral ele-
ment of the drug development process to effectively support
decision-making.  Good management of the working group
preferably by an experienced and competent company asso-
ciate is crucial for assuring an objective-oriented process
taking both scientific and business relevant aspects into
account. 228 Adverse Preclinical Findings—2
Additional tailor-made studies to further characterize
an APF and to obtain insights into the MoA of the drug can-
didate must be carefully designed to obtain interpretable
results.  As shown in the first part of this review, the most
important parameters in the overall WoE approach regarding
relevance of APFs for man are 
• Safety ratios comparing animal exposure at the NOAEL
and human therapeutic exposure, permitting a quantita-
tive prediction of the relevance of the finding for man. 
• MoA helping to understand the qualitative relevance of
the finding for man, where possible.  If the MoA proves
that an APF is not relevant to man, then no safety ratios
are necessary.
The MoA of drug candidates with potential genotoxic-
ity and teratogenicity can often not be established.  Generally
no clinical data will become available to supersede preclini-
cal data.  While a sufficient safety ratio may help in case of
equivocal genotoxicity, this is not the case for potential ter-
atogens, thus limiting the use of such drugs in women of
childbearing potential or pregnant women.
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